China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab (REMD-477), a Category 1 drug developed by Beijing CoSci-REMD Bio Med-Tech Co, Ltd (CoSci-REMD Bio), a subsidiary of U.S. biotech REMD Biotherapeutics Inc., has received clearance for clinical study in type 1 diabetes in China.
Volagidemab’s Mechanism and Clinical Progress
Volagidemab is a glucagon receptor (GCGR) targeting antibody candidate for the treatment of both type 1 and type 2 diabetes. It can specifically bind to GCGR, blocking the glucagon pathway, which inhibits excessive endogenous blood glucose production and avoids the risk of ketoacidosis. This drug has already completed a Phase II study in type 1 diabetes patients in the U.S. with positive preliminary results. To date, no similar product has been approved for marketing globally.- Flcube.com
